{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:53:19Z","timestamp":1787003599985,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19ck0106305h0003"],"award-info":[{"award-number":["19ck0106305h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Somatic genetic alteration analysis was performed for post-hysterectomy high-risk early-stage uterine cervical cancer patients who underwent post-operative radiation therapy. Post-operative radiation therapy was performed for patients with pathological features of pelvic lymph node metastasis, parametrium invasion, or positive vaginal margin, which corresponded to the post-operative high-risk category. DNA was extracted from paraffin-embedded surgical specimens, and 50 somatic hotspot genetic alternations were detected using Ion AmpliSeq Cancer Hotspot Panel. The existence of actionable mutation was assessed based on OncoKB evidence level\u2009&gt;\u20093A. Between January 2008 and November 2019, 89 patients who underwent abdominal radical hysterectomy followed by post-operative radiation therapy were identified. The follow-up period for living patients was 82.3 months (range 9.3\u2013153.9), and the 5-year relapse-free survival and overall survival rates were 72.6% and 85.9%, respectively. The most frequently detected somatic mutation was\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    (26 [29.2%] patients); however, no prognostic somatic genetic alterations were identified. Actionable mutations were detected in 30 (33.7%) patients. Actionable mutations were detected in approximately one-third of patients, suggesting that precision medicine can be offered to patients with post-operative high-risk uterine cervical cancer in the near future.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-90139-0","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T06:03:08Z","timestamp":1621404188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Distribution of genetic alterations in high-risk early-stage cervical cancer patients treated with postoperative radiation therapy"],"prefix":"10.1038","volume":"11","author":[{"given":"Naoya","family":"Murakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Asami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takayanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sou","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikumi","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniko","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kae","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyasu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouya","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Itami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"90139_CR1","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1002\/cam4.1155","volume":"6","author":"TF Schwarz","year":"2017","unstructured":"Schwarz, T. F. et al. Ten-year immune persistence and safety of the HPV-16\/18 AS04-adjuvanted vaccine in females vaccinated at 15\u201355 years of age. Cancer Med. 6, 2723\u20132731. https:\/\/doi.org\/10.1002\/cam4.1155 (2017).","journal-title":"Cancer Med."},{"key":"90139_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1405044","volume":"372","author":"EA Joura","year":"2015","unstructured":"Joura, E. A. et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N. Engl. J. Med. 372, 711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1405044 (2015).","journal-title":"N. Engl. J. Med."},{"key":"90139_CR3","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1016\/j.vaccine.2018.05.019","volume":"36","author":"J Dillner","year":"2018","unstructured":"Dillner, J. et al. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. Vaccine 36, 3820\u20133829. https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.019 (2018).","journal-title":"Vaccine"},{"key":"90139_CR4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/jjco\/hyv097","volume":"45","author":"M Hori","year":"2015","unstructured":"Hori, M. & Katanoda, K. Morphological distribution of cervical and corpus uteri cancer from Cancer Incidence in Five Continents . Jpn. J. Clin. Oncol. 45, 697. https:\/\/doi.org\/10.1093\/jjco\/hyv097 (2015).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"90139_CR5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/jjco\/hyv002","volume":"45","author":"K Katanoda","year":"2015","unstructured":"Katanoda, K. et al. An updated report on the trends in cancer incidence and mortality in Japan, 1958\u20132013. Jpn. J. Clin. Oncol. 45, 390\u2013401. https:\/\/doi.org\/10.1093\/jjco\/hyv002 (2015).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"90139_CR6","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/jjco\/hyv088","volume":"45","author":"M Hori","year":"2015","unstructured":"Hori, M. et al. Cancer incidence and incidence rates in Japan in 2009: A study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn. J. Clin. Oncol. 45, 884\u2013891. https:\/\/doi.org\/10.1093\/jjco\/hyv088 (2015).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"90139_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1006\/gyno.1999.5387","volume":"73","author":"A Sedlis","year":"1999","unstructured":"Sedlis, A. et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol. Oncol. 73, 177\u2013183. https:\/\/doi.org\/10.1006\/gyno.1999.5387 (1999).","journal-title":"Gynecol. Oncol."},{"key":"90139_CR8","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2000.18.8.1606","volume":"18","author":"WA Peters 3rd","year":"2000","unstructured":"Peters, W. A. 3rd. et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 18, 1606\u20131613. https:\/\/doi.org\/10.1200\/JCO.2000.18.8.1606 (2000).","journal-title":"J. Clin. Oncol."},{"key":"90139_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature21386","volume":"543","author":"Cancer Genome Atlas Research Network","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature 543, 378\u2013384. https:\/\/doi.org\/10.1038\/nature21386 (2017).","journal-title":"Nature"},{"key":"90139_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-018-1351-y","volume":"24","author":"Y Ebina","year":"2019","unstructured":"Ebina, Y. et al. Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer. Int. J. Clin. Oncol. 24, 1\u201319. https:\/\/doi.org\/10.1007\/s10147-018-1351-y (2019).","journal-title":"Int. J. Clin. Oncol."},{"key":"90139_CR11","volume-title":"The General Rules for Clinical and Pathological Management of Uterine Cervical Cancer","author":"Japan Society of Obstetrics and Gynecology","year":"2012","unstructured":"Japan Society of Obstetrics and Gynecology. The General Rules for Clinical and Pathological Management of Uterine Cervical Cancer 3rd edn. (Kanahara & Co Ltd, 2012).","edition":"3"},{"key":"90139_CR12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/jrr\/rrz041","volume":"60","author":"K Tsuchida","year":"2019","unstructured":"Tsuchida, K. et al. Postoperative pelvic intensity-modulated radiation therapy reduced the incidence of late gastrointestinal complications for uterine cervical cancer patients. J. Radiat. Res. 60, 650\u2013657. https:\/\/doi.org\/10.1093\/jrr\/rrz041 (2019).","journal-title":"J. Radiat. Res."},{"key":"90139_CR13","doi-asserted-by":"publisher","first-page":"15050","DOI":"10.1038\/hgv.2015.50","volume":"2","author":"Y Yamaguchi-Kabata","year":"2015","unstructured":"Yamaguchi-Kabata, Y. et al. iJGVD: An integrative Japanese genome variation database based on whole-genome sequencing. Hum. Genome Var. 2, 15050. https:\/\/doi.org\/10.1038\/hgv.2015.50 (2015).","journal-title":"Hum. Genome Var."},{"key":"90139_CR14","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: Improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062\u2013D1067. https:\/\/doi.org\/10.1093\/nar\/gkx1153 (2018).","journal-title":"Nucleic Acids Res."},{"key":"90139_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nature12881","volume":"506","author":"AI Ojesina","year":"2014","unstructured":"Ojesina, A. I. et al. Landscape of genomic alterations in cervical carcinomas. Nature 506, 371\u2013375. https:\/\/doi.org\/10.1038\/nature12881 (2014).","journal-title":"Nature"},{"key":"90139_CR16","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1158\/0008-5472.CAN-17-0337","volume":"77","author":"JT Robinson","year":"2017","unstructured":"Robinson, J. T., Thorvaldsd\u00f3ttir, H., Wenger, A. M., Zehir, A. & Mesirov, J. P. Variant review with the integrative genomics viewer. Cancer Res. 77, e31\u2013e34. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0337 (2017).","journal-title":"Cancer Res."},{"key":"90139_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ygyno.2019.10.022","volume":"156","author":"S Hirose","year":"2020","unstructured":"Hirose, S. et al. Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients. Gynecol. Oncol. 156, 203\u2013210. https:\/\/doi.org\/10.1016\/j.ygyno.2019.10.022 (2020).","journal-title":"Gynecol. Oncol."},{"key":"90139_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3346\/jkms.2009.24.4.579","volume":"24","author":"JH Hong","year":"2009","unstructured":"Hong, J. H., Song, S. H., Kim, J. K., Han, J. H. & Lee, J. K. Comparison of the novel human papillomavirus 4 auto-capillary electrophoresis test with the hybrid capture 2 assay and with the PCR HPV typing set test in the detection of high-risk HPV including HPV 16 and 18 genotypes in cervical specimens. J. Korean Med. Sci. 24, 579\u2013584. https:\/\/doi.org\/10.3346\/jkms.2009.24.4.579 (2009).","journal-title":"J. Korean Med. Sci."},{"key":"90139_CR19","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1128\/JCM.28.12.2739-2743.1990","volume":"28","author":"AJ van den Brule","year":"1990","unstructured":"van den Brule, A. J., Meijer, C. J., Bakels, V., Kenemans, P. & Walboomers, J. M. Rapid detection of human papillomavirus in cervical scrapes by combined general primer-mediated and type-specific polymerase chain reaction. J. Clin. Microbiol. 28, 2739\u20132743. https:\/\/doi.org\/10.1128\/JCM.28.12.2739-2743.1990 (1990).","journal-title":"J. Clin. Microbiol."},{"key":"90139_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00011","volume":"2017","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty, D. et al. OncoKB: A precision oncology knowledge base. JCO Precis. Oncol. 2017, 1\u201316. https:\/\/doi.org\/10.1200\/PO.17.00011 (2017).","journal-title":"JCO Precis. Oncol."},{"key":"90139_CR21","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/cas.13969","volume":"110","author":"K Sunami","year":"2019","unstructured":"Sunami, K. et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Sci. 110, 1480\u20131490. https:\/\/doi.org\/10.1111\/cas.13969 (2019).","journal-title":"Cancer Sci."},{"key":"90139_CR22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489\u2013501. https:\/\/doi.org\/10.1038\/nrc839 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"90139_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/sj.bjc.6602970","volume":"94","author":"B Karakas","year":"2006","unstructured":"Karakas, B., Bachman, K. E. & Park, B. H. Mutation of the PIK3CA oncogene in human cancers. Br. J. Cancer 94, 455\u2013459. https:\/\/doi.org\/10.1038\/sj.bjc.6602970 (2006).","journal-title":"Br. J. Cancer"},{"key":"90139_CR24","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1001\/jamaoncol.2016.0891","volume":"2","author":"SZ Millis","year":"2016","unstructured":"Millis, S. Z., Ikeda, S., Reddy, S., Gatalica, Z. & Kurzrock, R. Landscape of phosphatidylinositol-3-kinase pathway alterations across 19784 diverse solid tumors. JAMA Oncol. 2, 1565\u20131573. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0891 (2016).","journal-title":"JAMA Oncol."},{"key":"90139_CR25","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","volume":"34","author":"PM LoRusso","year":"2016","unstructured":"LoRusso, P. M. Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors. J. Clin. Oncol. 34, 3803\u20133815. https:\/\/doi.org\/10.1200\/JCO.2014.59.0018 (2016).","journal-title":"J. Clin. Oncol."},{"key":"90139_CR26","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","volume":"28","author":"KD Courtney","year":"2010","unstructured":"Courtney, K. D., Corcoran, R. B. & Engelman, J. A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28, 1075\u20131083. https:\/\/doi.org\/10.1200\/JCO.2009.25.3641 (2010).","journal-title":"J. Clin. Oncol."},{"key":"90139_CR27","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554. https:\/\/doi.org\/10.1126\/science.1096502 (2004).","journal-title":"Science"},{"key":"90139_CR28","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9, F. et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380, 1929\u20131940. https:\/\/doi.org\/10.1056\/NEJMoa1813904 (2019).","journal-title":"N. Engl. J. Med."},{"key":"90139_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ygyno.2009.03.026","volume":"114","author":"T Kasamatsu","year":"2009","unstructured":"Kasamatsu, T., Onda, T., Sawada, M., Kato, T. & Ikeda, S. Radical hysterectomy for FIGO stage IIB cervical cancer: Clinicopathological characteristics and prognostic evaluation. Gynecol. Oncol. 114, 69\u201374. https:\/\/doi.org\/10.1016\/j.ygyno.2009.03.026 (2009).","journal-title":"Gynecol. Oncol."},{"key":"90139_CR30","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1006\/gyno.1999.5527","volume":"75","author":"CS Tsai","year":"1999","unstructured":"Tsai, C. S. et al. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy. Gynecol. Oncol. 75, 328\u2013333. https:\/\/doi.org\/10.1006\/gyno.1999.5527 (1999).","journal-title":"Gynecol. Oncol."},{"key":"90139_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1006\/gyno.1998.5005","volume":"70","author":"M Okada","year":"1998","unstructured":"Okada, M. et al. Indication and efficacy of radiation therapy following radical surgery in patients with stage IB to IIB cervical cancer. Gynecol. Oncol. 70, 61\u201364. https:\/\/doi.org\/10.1006\/gyno.1998.5005 (1998).","journal-title":"Gynecol. Oncol."},{"key":"90139_CR32","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.ygyno.2020.08.020","volume":"159","author":"Y Yoshimoto","year":"2020","unstructured":"Yoshimoto, Y. et al. Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy. Gynecol. Oncol. 159, 546\u2013553. https:\/\/doi.org\/10.1016\/j.ygyno.2020.08.020 (2020).","journal-title":"Gynecol. Oncol."},{"key":"90139_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/1471-0528.13071","volume":"122","author":"L Rodr\u00edguez-Carunchio","year":"2015","unstructured":"Rodr\u00edguez-Carunchio, L. et al. HPV-negative carcinoma of the uterine cervix: A distinct type of cervical cancer with poor prognosis. BJOG 122, 119\u2013127. https:\/\/doi.org\/10.1111\/1471-0528.13071 (2015).","journal-title":"BJOG"},{"key":"90139_CR34","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","volume":"370","author":"KS Tewari","year":"2014","unstructured":"Tewari, K. S. et al. Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med. 370, 734\u2013743. https:\/\/doi.org\/10.1056\/NEJMoa1309748 (2014).","journal-title":"N. Engl. J. Med."},{"key":"90139_CR35","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383, 1207\u20131217. https:\/\/doi.org\/10.1056\/NEJMoa1917239 (2020).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90139-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90139-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90139-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T03:22:33Z","timestamp":1670037753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90139-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["90139"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-90139-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"assertion":[{"value":"21 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Itami receives personal fees from HekaBio and from kay J \noutside the submitted work. The rest of the authors have no conflicts of \ninterest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10567"}}